Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Pro
Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) progr...
Source: pharmiweb.com